Monte Rosa Therapeutics Inc (GLUE) FinancialsGLUEMonte Rosa Therapeutics Inc

Evaluating the bottom line, Monte Rosa Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -547.84%, while the net margin is -483.91%. These profitability ratios, combined with a Return on Equity (ROE) of -42.66%, provide a clear picture of how effectively GLUE converts its operational activities into shareholder value.

In the context of the broader market, GLUE competes directly with industry leaders such as ODTX and KURA. With a market capitalization of $969.16M, it holds a leading position in the sector. When comparing efficiency, GLUE's gross margin of 100.00% stands against ODTX's N/A and KURA's 98.84%. Such benchmarking helps identify whether Monte Rosa Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has reported significant revenue fluctuations, with Q1 2026 revenue at $4.21 million and Q2 2026 at $8.97 million, but it has also faced substantial net losses, such as -$44.5 million in Q1 2026.